久久午夜影院,国产大鸡巴九色,丰满人妻一区=区三区在线视频53,五月天婷婷激情四射在线观看

    <source id="7npa8"><tr id="7npa8"><dfn id="7npa8"></dfn></tr></source>
    1. 產(chǎn)品中心您現(xiàn)在的位置:首頁 > 產(chǎn)品展示 > > 免疫佐劑 > ODN 1826 VacciGrade™

      ODN 1826 VacciGrade™

      更新時間:2022-01-28

      簡要描述:

      CpG ODN, type B (murine) - TLR9-based adjuvant CpG ODN 1826 is a synthetic immunostimulatory oligonucleotide (ODN) that contains unmethylated CpG dinucleotides.ODN 1826 is a class B CpG ODN specific……

      型號:廠商性質(zhì):代理商瀏覽量:1064

      CpG ODN, type B (murine) - TLR9-based adjuvant

      CpG ODN 1826 is a synthetic immunostimulatory oligonucleotide (ODN) that contains unmethylated CpG dinucleotides.

      ODN 1826 is a class B CpG ODN specific for mouse Toll-like receptor 9 (TLR9). It strongly activates B cells, weakly stimulates IFN-α secretion in pDCs and generates Th1-dominant immune responses.

      ODN 1826 VacciGrade™ is prepared under strict aseptic conditions. It is guaranteed sterile and has been thoroughly tested to confirm the absence of endotoxins. ODN 1826 VacciGrade™ is suitable for preclinical studies.

      ODN 1826 VacciGrade™ is for research use only; it is not for use in humans.


      Specifications

      Specificity: Th1 response

      Working concentration: 20 - 50 μg/mouse

      Quality: Sterile, Endotoxin level

      Solubility: 2 mg/ml in physiological water

      Quality control:
      ODN 1826 VacciGrade™ is a preclinical grade preparation of the CpG ODN 1826. It is prepared under strict aseptic conditions.
      It is tested for sterility and the presence of endotoxins.
      ODN 1826 VacciGrade™ is guaranteed sterile and its endotoxin level is ODN1826 sequence: 5’-tccatgacgttcctgacgtt-3’ (20 mer)


      Contents

      ODN 1826 VacciGrade™ is provided lyophilized width:

      • 1 mg (157.1 nmol) of sterile lyophilized ODN 1826 VacciGrade™

      • 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

       ODN 1826 VacciGrade™ is shipped at room temperature

       Upon receipt it should be stored at -20°C for up to 1 year.

      Upon resuspension, prepare aliquots of ODN 1826 VacciGrade™ and store at -20°C.

      Product is stable 6 months at -20°C when properly stored.

      Avoid repeated freeze-thaw cycles.


      Details

      Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs), such as ODN 1826, have been extensively studied as adjuvants [1].

      These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2].

      CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses  [3].

      Pre-clinical studies, conducted in rodents and non-human primates, and human clinical trials have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses  [1].

      Three types of stimulatory CpG ODNs have been identified, types A, B and C, which differ in their immune-stimulatory activities  [4-5]. Furthermore, CpG ODNs activate TLR9 in a species-specific manner  [6].

      ODN 1826 is a type B CpG ODN specific for mouse TLR9. Type B CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides and can strongly activate B cells  [4].

      ODN 1826 has been tested as an adjuvant in numerous animal models  [7-9].

      Research in mice demonstrated that ODN 1826 administration can induce the activation of antigen presenting cells8 and type I IFN anti-viral activity [8-9], indicative of a Th1 immune response.
       

      1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
      2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-5.
      3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
      4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
      5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
      6. Bauer S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. PNAS, 98(16):9237-42.
      7. Xiong Z. et al., 2008. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res 14: 5484-93.
      8. Longhi MP. et al., 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-602.
      9. Ank MB. et al., 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-85.

      如需購買或咨詢該產(chǎn)品技術(shù)問題,請聯(lián)系Invivogen一級代理商-欣博盛生物

      留言框

      • 產(chǎn)品:

      • 您的單位:

      • 您的姓名:

      • 聯(lián)系電話:

      • 常用郵箱:

      • 省份:

      • 詳細地址:

      • 補充說明:

      • 驗證碼:

        請輸入計算結(jié)果(填寫阿拉伯數(shù)字),如:三加四=7

      上一篇:ODN 2006 (ODN 7909)

      下一篇:ODN 1826

      返回列表>>